- Short report
- Open Access
The effect of deletion of the orphan G – protein coupled receptor (GPCR) gene MrgE on pain-like behaviours in mice
© Cox et al; licensee BioMed Central Ltd. 2008
- Received: 01 October 2007
- Accepted: 15 January 2008
- Published: 15 January 2008
The orphan GPCR MrgE is one of an extended family of GPCRs that are expressed in dorsal root ganglia (DRG). Based on these expression patterns it has been suggested that GPCRs like MrgE may play a role in nociception however, to date, no direct supporting evidence has emerged. We generated mutant mice lacking MrgE and examined the effects of deletion of this gene in three pain behavioural models. The effect of MrgE gene deletion on expression of Mrgs and genes involved in sensory neurone function was also investigated.
The absence of MrgE had no effect on the development of pain responses to a noxious chemical stimulus or an acute thermal stimulus. However, in contrast, the development but not the maintenance of neuropathic pain was affected by deletion of MrgE. The expression of Mrg genes was not significantly affected in the MrgE knockout (KO) mice with the sole exception of MrgF. In addition, the expression of 77 of 84 genes involved in sensory neuron development and function was also unaffected by deletion of MrgE. Of the 7 genes affected by MrgE deletion, 4 have previously been implicated in nociception.
The data suggests that MrgE may play a role in selective pain behavioural responses in mice.
- Dorsal Root Ganglion
- Sciatic Nerve
- Chronic Constriction Injury
- Nocifensive Behaviour
- Hotplate Test
Mrg-receptors, first described in 2001 , constitute a family of G-protein coupled receptors in which certain members are expressed in distinct subsets of sensory neurons, known to play a role in nociception, and were activated by peptides that had previously been functionally linked to pain. Indirect physiological evidence for a role for MrgC, in particular, was provided by the demonstration that peptides known to activate MrgC elicited pain-like behaviours on administration to rats . Recently it has been shown that levels of one of these peptides, Bovine Adrenal Medulla peptide 22, was increased in superficial laminae of the spinal cord (SC) and in DRG cells following complete freunds adjuvant induced inflammation . However the specificity of these peptides for MrgC has not been conclusively demonstrated, therefore non-MrgC mediated effects cannot be ruled out. Expression of rat MrgC and MrgA is down regulated in DRG following spinal nerve ligation provided additional evidence that these receptors are somehow functionally linked to pain . Elegant studies with genetically modified mice demonstrated that MrgD is uniquely expressed in primary afferent nerve fibres but pain behavioural phenotypes for mice lacking this receptor were not reported . The MrgD ligand, beta-alanine, inhibited potassium channel mediated M-current activity in both a recombinant cell system and primary DRG neurons suggesting that activation of MrgD could inhibit the M-current resulting in repetitive firing of normally phasic nociceptive neurons leading to pain . Similarly activation of MrgX1 expressed in rat superior cervical ganglion neurons resulted in M-current inhibition .
A functional role for Mrg receptors in other systems could be assumed from the physiological functions of ligands known to activate these receptors. MrgX2 is activated by basic molecules  and cortistatin , amongst other ligands, and is therefore postulated to have a role in mast cell degranulation and neuroendocrine function respectively. Murine MrgA1 and MrgC11 are activated by RF-amide peptides  suggesting that these receptors could be involved in a variety of neuromodulatory functions attributed to these peptides . However, as with pain, direct physiological proof for a role for these receptors in these systems is lacking.
Study of members of this family is generally hampered by the lack of specific ligands and/or pharmacological tools. MrgE is an orphan receptor; however we and others have demonstrated that this receptor is largely restricted to the nervous system with greatest expression in SC and DRG . In the absence of suitable tools we have developed genetically modified mice lacking MrgE. The phenotype of MrgE KO mice was studied in a number of assays, with particular focus on pain behaviours. The effect of deletion of MrgE on expression of a selection of genes known to be expressed in sensory neurons, including other Mrgs, was also investigated.
Generation of MrgE KO mice
Behavioural testing of KO and WT mice
KO and WT mice were subjected to a battery of behavioural and biochemical tests. KO mice appeared to be normal in the majority of tests with some minor differences noted in blood biochemistry, sexual behaviour and prepulse startle responses. However no overt phenotypic abnormalities were identified (Data not shown).
Gene expression analysis
MrgE KO and WT mice are indistinguishable in the formalin and hotplate tests implying that MrgE plays no significant role in the response to noxious chemical and thermal stimuli respectively. Dong et al 2001 demonstrated that MrgD and MrgA1 are expressed in vanniloid receptor-1 (VR1) negative small diameter sensory neurones in the mouse, indicating that these receptors may be less important for the detection of noxious chemical stimuli. At present the detailed distribution of other Mrgs, including MrgE, in rodent DRG has not been determined. Taken together, the KO and distribution data would suggest that Mrgs, in general, may not be involved in the sensing of chemically induced pain, although this may not be the case for higher mammals where distribution of MrgD and E in VR1 positive and medium to large diameter neurones, respectively, was detected in DRG .
There was a significant difference between WT and KO mice in the rate they develop an increased hypersensitivity to the application of von Frey hairs. However the peak level of allodynia acquired, and maintained, was similar in both WT and KO mice. The slower rate of onset of allodynia in the KO animals suggests that MrgE plays a role in the development but not the maintenance of allodynia. Whether this behavioural effect is directly due to lack of functional MrgE in adult mice or has arisen due to the absence of MrgE during the development of the nervous system in KO animals remains to be seen. In the adult rat MrgE expression is significantly reduced as early as day 7 post CCI of the sciatic nerve lending further support to the notion that this gene may be involved in the development of allodynia. Down regulation of MrgE or a reduction in cells expressing MrgE may be an essential component of the temporal processes that affect the development of allodynia, therefore the complete absence of this gene deregulates these processes slowing the development of allodynia in the KO mice.
Emerging data and hypotheses suggest that cellular and functional plasticity involving neuro-immune interaction and neuronal long term facilitation, potentiation and depression in the periphery, at spinal and/or supraspinal sites may underlie behaviours such as allodynia associated with persistent pain states (For recent reviews see [14, 15]). Although MrgE is expressed at all tissue levels known to be involved in pain sensation, the KO data suggests that it has no role in maintaining the long term plastic changes that may underlie neuropathic pain. This notion is supported by the observation that KO and WT animals develop the same degree of allodynia.
The small but statistically significant down regulation of genes known to be involved in sensory neuron function and development is of interest and may also offer an explanation. It is tempting to speculate that reduction in the expression of these genes observed in the DRG of KO mice may reflect a reduction in the number of neurons that express these same genes. The loss of these sensory neurons may result in the observed deficit in the rate of development of allodynia. Deficits in pain-like behaviours have been demonstrated in GFR α-2Na v 1.7Na v 1.8[18, 19] and Runx-1 KO mice, although the extent and nature of these behavioural deficits are much more dramatic than those demonstrated with the MrgE KOs, possibly because of complete loss of expression of the genes under study.
The expression of only one Mrg, MrgF was shown to be altered by MrgE deletion. MrgD gene expression was unaffected by MrgE deletion although both these receptors have been shown to functionally associate in a recombinant cell system . Although speculative, upregulation of MrgF may compensate for the absence of MrgE therefore it would be interesting to determine if co-expression of MrgF had any effect on MrgD function, or if the pain behavioural phenotype of an MrgF MrgE double KO would be more profound than that observed with MrgE KOs.
The data presented in this paper is the first to demonstrate a role for the orphan GPCR MrgE in pain. The functional significance of MrgE deletion on pain will require extension of these studies to detailed molecular and immunohistochemical analysis of the KO mice, and further analysis of the effects of MrgE gene deletion on other pain endpoints and in other pain models.
Generation of MrgE KO mice
MrgE targeted ES clone was obtained from Deltagen (San Carlos, CA.). A genomic fragment containing the MrgE gene was isolated from a mouse genomic phage library. The targeting vector was assembled on the pGT-N28 backbone (NEB, Ipswich, MA) and so designed that a total of 776 bps from within the 930 base pair coding region located in exon 2 of MrgE gene (first exon is un-translated) was deleted and replaced with a 7,076 bp IRES-lacZ reporter and neomycin resistance cassette (IRES-LacZ-NEO) (see Fig. 1A). The targeting vector was linearized and electroporated into the E14 (129/Ola) mouse embryonic stem (ES) cells. ES cells were then cultured in the presence of the antibiotic G418/geneticin, and surviving colonies carrying the homologously integrated neo DNA were identified by PCR amplification, retrieving a 6.5 kb fragment, using a neo-specific reverse primer (#2416, 5'-ATCAGCTTACCATGGCCAAGATCCC-3') paired with a forward primer located 5' to the 5' homology arm (#71732, 5'-GACATCTCCCTAGTCCAGACGACTC-3'). Successful homologous recombination at the 3' end was also confirmed using a neo-specific forward primer (#1431, 5'-ACGTACTCGGATGGAAGCCGGTCTT-3') paired with a reverse primer located 3' to the 3' homology arm (#71738: 5'-CCTCCTTCTCTCTCCACGTGTTCCT-3'), retrieving a 7.0 kb fragment. Colonies that gave rise to the correct PCR products were confirmed by Southern blot analysis and presence of a single neo cassette in the genome was also confirmed by Southern blot analysis using a neo gene fragment as a probe (data not shown).
Targeted ES cells were injected into C57Bl/6J blastocysts and male chimeric mice were generated and bred with C57Bl/6J female mice to produce F1 heterozygous offspring. F1 germline mice were then bred to C57BL/6J wild type mice to expand the colony and heterozygote mice were interbred to produce the study population mice. All phenotypic analysis was performed on a hybrid C57Bl/6J/129 background. Genotyping to detect wild type, heterozygote and homozygote mice was performed using a multiplex PCR reaction, with a shared 5' forward primer (5'-GCA GAC ATC AGC CAT GAC GT-3') and a 3' reverse primer unique to the targeted allele (#2416, 5'-ATC AGC TTA CCA TGG CCA AGA TCC C-3') or to the MrgE locus (5'-ATC TAT CTC TTG GAT GTG GCC TG-3'). The WT product is 201 and mutant allele 922 bps (see Fig. 1B).
Behavioural testing of KO and WT mice
All animals were handled in accordance with Pfizer policy on animal welfare and with regional government legislation on the use of animals in research.
The spontaneous locomotor activity of the mice was measured by placing the animals in a novel environment which is monitored for 1 hr in a 35 × 20 cm perspex chamber equipped with a series of two photocells located at 1 and 10 cm above the floor. Each animal was placed in the centre of the cage and total locomotor activity (ambulation and rearing) was monitored every 5 min and recorded as activity counts as the beams were broken. Activity data was captured on computer. Mice were randomly placed in the photo beam equipped cages.
Acute pain responses were assessed using the formalin and hotplate tests. Mice were subjected to the formalin test as follows. Homozygote KO mice and WT littermates were habituated to perspex boxes for 15 minutes before 20 ul of 5% formalin was administered into the plantar surface of the right hind paw. Nocifensive behaviour was assessed by measuring the time spent licking and biting in 5-minute bins for 45 minutes following formalin injection.
Neuropathic pain behaviours in mice were assessed following CCI of the right sciatic nerve based on previously described methods . Mice were placed in an anaesthetic chamber and anaesthetised with a 2% isofluorane O2 mixture. The right hind thigh was shaved and swabbed with 1% iodine. Animals were then transferred to a homeothermic blanket for the duration of the procedure and anaesthesia maintained during surgery via a nose cone. The skin was cut along the line of the thighbone and the common sciatic nerve was exposed at the middle of the thigh by blunt dissection through biceps femoris. Three ligatures (4-0 silk) were tied loosely around the nerve, the wound was closed and the animals allowed to recover. Following surgery the development of static allodynia was monitored regularly over a period of 4 weeks. Static allodynia was evaluated by application of von Frey hairs (Stoelting, Wood Dale, Illinois, U.S.A) in ascending order of force (0.008, 0.02, 0.04, 0.07, 0.16, 0.4, 0.6, 1, 1.4, 2, 4 grams) to the plantar surface of hind paws. Each von Frey hair was applied to the paw for a maximum of 6 seconds, or until a withdrawal response occurred. Once a withdrawal response was established, the paw was re-tested, starting with the filament below. The lowest amount of force required to elicit a response was recorded as paw withdrawal threshold (PWT) in grams. Static allodynia was defined as present if animals responded to a force equal to or less than, 0.04 g, which is innocuous in normal mice. CCI of the rat sciatic nerve was performed as described previously .
Gene expression analysis
Mrg family members and genes important for sensory neuron development and function were quantified in various tissues from adult WT and MrgE KO mice by quantitative RTPCR analysis. DRG, SC and brain tissues (n = 6) were harvested from KO and WT mice, stored in RNAlater (Ambion) at -20°C. Tissues were mechanically homogenised using Powergen 125 (Fisher) in 600 ul Buffer RLT (Qiagen) containing β-Mercaptoethanol (10 ul/ml RLT). SCs and brains were homogenised whole in larger volumes (1.2 ml and 6 ml) accordingly and RNA was extracted as per the RNeasy tissue protocol (Qiagen) with on column DNaseI treatment. Brains and SCs were also treated with Amplification Grade DNaseI (Invitrogen) in accordance with the manufacturer's instructions. RNA was reverse transcribed using the GeneAmp RNA PCR kit (Applied Biosystems) and 15 ng/well equivalent of cDNA used in quantitative PCR TaqMan® to determine gene expression levels of MrgC11, D, E and G using custom oligos (Sigma) and MrgF, H and PR4 using Assays on Demand™ (Applied Biosystems). Arbitrary copy number (ACN) was calculated using the formula ACN = 10(12-(0.3xCt)). Multiple gene profiling of the DRGs was performed using 1 ng cDNA per well on a custom RT2 PCR profiler array (SuperArray) and the data analysed using Spotfire Decision site 8.1. The ACN +/-standard deviation was calculated as described. Sciatic nerve was harvested from rats 7, 14 and 21 days post CCI. RNA was isolated from sciatic nerve ipsilateral and contralateral to the injured nerve. cDNA was synthesized from isolated sciatic nerve RNA as described for murine RNA. 25 ng/well of cDNA equivalent was used as template in rat MrgE specific TaqMan assays and the data generated analysed using a ΔΔCt method (Applied Biosystems). Ipsilateral versus contralateral levels of MrgE were compared for each time point post surgery and expressed as relative copy number. The sequences of all primers and probes used in this study are available on request.
We would like to acknowledge our colleagues Dic Williams and Laura Corradini for helpful suggestions, Mary K. Bauchmann for expanding the ES clones, Jeffrey L. Stock and Diane M.Z. Nadeau for performing blastocyst injection and Janice B. Drummond, Joanne L. Jeffries-Griffor, and Janis O'Quinn Vajdos for genotyping the mice.
- Dong X, Han S, Zylka MJ, Simon MI, Anderson DJ: A diverse family of GPCRs expressed in specific subsets of nociceptive sensory neurons. Cell 2001, 106(5):619–632. 10.1016/S0092-8674(01)00483-4View ArticlePubMedGoogle Scholar
- Grazzini E, Puma C, Roy MO, Yu XH, O'Donnell D, Schmidt R, Dautrey S, Ducharme J, Perkins M, Panetta R, Laird JMA, Ahmad S, Lembo PMC: Sensory neuron-specific receptor activation elicits central and peripheral nociceptive effects in rats. Proceedings of the National Academy of Sciences of the United Statesof America 2004, 101(18):7175–7180. 10.1073/pnas.0307185101View ArticleGoogle Scholar
- Cai M, Chen T, Quirion R, Hong Y: The involvement of spinal bovine adrenal medulla 22-like peptide, the proenkephalin derivative, in modulation of nociceptive processing. Eur J Neurosci 2007/09/05 edition. 2007, 26(5):1128–1138. 10.1111/j.1460-9568.2007.05755.xView ArticlePubMedGoogle Scholar
- Gustafson EL, Maguire M, Campanella M, Tarozzo G, Jia Y, Dong XW, Laverty M, Murgolo N, Priestley T, Reggiani A, Monsma F, Beltramo M: Regulation of two rat mas-related genes in a model of neuropathic pain. Brain research Molecular brain research 2005, 142(1):58–64. 10.1016/j.molbrainres.2005.09.014View ArticlePubMedGoogle Scholar
- Zylka MJ, Rice FL, Anderson DJ: Topographically distinct epidermal nociceptive circuits revealed by axonal tracers targeted to Mrgprd. Neuron 2005, 45(1):17–25. 10.1016/j.neuron.2004.12.015View ArticlePubMedGoogle Scholar
- Crozier RA, Ajit SK, Kaftan EJ, Pausch MH: MrgD activation inhibits KCNQ/M-currents and contributes to enhanced neuronal excitability. J Neurosci 2007/04/20 edition. 2007, 27(16):4492–4496. 10.1523/JNEUROSCI.4932-06.2007View ArticlePubMedGoogle Scholar
- Chen H, Ikeda SR: Modulation of ion channels and synaptic transmission by a human sensory neuron-specific G-protein-coupled receptor, SNSR4/mrgX1, heterologously expressed in cultured rat neurons. J Neurosci 2004/05/28 edition. 2004, 24(21):5044–5053. 10.1523/JNEUROSCI.0990-04.2004View ArticlePubMedGoogle Scholar
- Tatemoto K, Nozaki Y, Tsuda R, Konno S, Tomura K, Furuno M, Ogasawara H, Edamura K, Takagi H, Iwamura H, Noguchi M, Naito T: Immunoglobulin E-independent activation of mast cell is mediated by Mrg receptors. Biochem Biophys Res Commun 2006/09/19 edition. 2006, 349(4):1322–1328. 10.1016/j.bbrc.2006.08.177View ArticlePubMedGoogle Scholar
- Robas N, Mead E, Fidock M: MrgX2 is a high potency cortistatin receptor expressed in dorsal root ganglion. The Journal of biological chemistry 2003, 278(45):44400–44404. 10.1074/jbc.M302456200View ArticlePubMedGoogle Scholar
- Han SK, Dong X, Hwang JI, Zylka MJ, Anderson DJ, Simon MI: Orphan G protein-coupled receptors MrgA1 and MrgC11 are distinctively activated by RF-amide-related peptides through the Galpha q/11 pathway. Proc Natl Acad Sci U S A 2002/10/25 edition. 2002, 99(23):14740–14745. 10.1073/pnas.192565799PubMed CentralView ArticlePubMedGoogle Scholar
- Fukusumi S, Fujii R, Hinuma S: Recent advances in mammalian RFamide peptides: the discovery and functional analyses of PrRP, RFRPs and QRFP. Peptides 2006/02/28 edition. 2006, 27(5):1073–1086. 10.1016/j.peptides.2005.06.031View ArticlePubMedGoogle Scholar
- Milasta S, Pediani J, Appelbe S, Trim S, Wyatt M, Cox P, Fidock M, Milligan G: Interactions between the Mas-related receptors MrgD and MrgE alter signalling and trafficking of MrgD. Molecular pharmacology 2006, 69(2):479–491. 10.1124/mol.105.018788View ArticlePubMedGoogle Scholar
- Zhang L, Taylor N, Xie Y, Ford R, Johnson J, Paulsen JE, Bates B: Cloning and expression of MRG receptors in macaque, mouse, and human. Brain research Molecular brain research 2005, 133(2):187–197. 10.1016/j.molbrainres.2004.10.007View ArticlePubMedGoogle Scholar
- Scholz J, Woolf CJ: The neuropathic pain triad: neurons, immune cells and glia. Nat Neurosci 2007, 10(11):1361–1368. 10.1038/nn1992View ArticlePubMedGoogle Scholar
- Zhuo M: Neuronal mechanism for neuropathic pain. Mol Pain 2007, 3: 14. 10.1186/1744-8069-3-14PubMed CentralView ArticlePubMedGoogle Scholar
- Lindfors PH, Võikar V, Rossi J, Airaksinen MS: Deficient nonpeptidergic epidermis innervation and reduced inflammatory pain in glial cell line-derived neurotrophic factor family receptor alpha2 knock-out mice. The Journal of Neuroscience: the official journal of the Society for Neuroscience 2006, 26(7):1953–1960.View ArticleGoogle Scholar
- Nassar MA, Stirling LC, Forlani G, Baker MD, Matthews EA, Dickenson AH, Wood JN: Nociceptor-specific gene deletion reveals a major role for Nav17 PN1 in acute and inflammatory pain. Proceedings of the National Academy of Sciences of the United Statesof America 2004, 101(34):12706–12711. 10.1073/pnas.0404915101View ArticleGoogle Scholar
- Akopian AN, Souslova V, England S, Okuse K, Ogata N, Ure J, Smith A, Kerr BJ, McMahon SB, Boyce S, Hill R, Stanfa LC, Dickenson AH, Wood JN: The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways. Nature neuroscience 1999, 2(6):541–548. 10.1038/9195View ArticlePubMedGoogle Scholar
- Laird JMA, Souslova V, Wood JN, Cervero F: Deficits in visceral pain and referred hyperalgesia in Nav18 SNS /PN3-null mice. The Journal of Neuroscience: the official journal of the Society for Neuroscience 2002, 22(19):8352–8356.Google Scholar
- Chen CL, Broom DC, Liu Y, de NJC, Li Z, Cen C, Samad OA, Jessell TM, Woolf CJ, Ma Q: Runx1 determines nociceptive sensory neuron phenotype and is required for thermal and neuropathic pain. Neuron 2006, 49(3):365–377. 10.1016/j.neuron.2005.10.036View ArticlePubMedGoogle Scholar
- Field MJ, Bramwell S, Hughes J, Singh L: Detection of static and dynamic components of mechanical allodynia in rat models of neuropathic pain: are they signalled by distinct primary sensory neurones? Pain 1999, 83(2):303–311. 10.1016/S0304-3959(99)00111-6View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.